



Paris, October 6, 2021, 7:30 a.m.

Icade postpones Icade Santé's IPO until market conditions improve

Icade and its minority shareholders have decided to postpone Icade Santé's planned IPO due to particularly volatile conditions in equity markets.

These conditions have made it impossible to proceed with the planned IPO initiated on September 22, 2021 on terms that are satisfactory to the company and its shareholders.

With the support of all its shareholders, Icade Santé's management will remain fully committed to further advancing its growth plan.

ABOUT ICADE

Desirable places to live

As an office and healthcare property investment company (portfolio worth €14.8bn on a full consolidation basis as of 06/30/2021) and a developer of homes, offices and public amenities (2020 economic revenue of €825m), Icade designs, builds, manages and invests in cities, neighbourhoods and buildings that are innovative, diverse, inclusive and connected, with a reduced carbon footprint. Desirable places to live and work. In collaboration with its stakeholders, Icade has made low carbon a strategic priority in order to reinvent real estate and create cities that are healthier, happier and more hospitable. Icade is a key player in Greater Paris and major French cities. It is listed as a "SIIC" on Euronext Paris and its leading shareholder is the Caisse des Dépôts group.

ABOUT ICADE SANTE

Places that care for people

Icade Santé is a European leader in healthcare real estate dedicated to helping healthcare and senior services providers successfully execute their sale-and-leaseback and property development strategies. The Group's teams have wide-ranging expertise in real estate investment, complex project management and in-depth knowledge of the challenges facing the healthcare sector. As of June 30, 2021, Icade Santé owned 183 properties, representing assets worth €6.0 billion (€6.4 billion, including duties) and a total leasable floor area of around 2.04 million sq.m.

The text of this press release is available on the Icade website: www.icafe.fr/en/ and on the Icade Santé website: www.icafe-sante.eu.

CONTACTS

Charlotte Pajaud-Blanchard
Press Relations Manager
+33 (0)1 41 57 71 19
charlotte.pajaud-blanchard@icafe.fr

Anne-Sophie Lanaute
Head of Financial Communication
and Investor Relations at Icade
+33 (0)1 41 57 70 29
anne-sophie.lanaute@icafe.fr

Yoann Nguyen
Investor Relations Manager
at Icade Santé
+33 (0)6 31 58 97 31
yoann.nguyen@icafe.fr

Havas Paris – France

Alienor Miens (+33 6 64 32 81 75, alienor.miens@havas.com)

Sarah Duparc (+33 6 46 72 39 99, sarah.duparc@havas.com)

Maitland – International

James Benjamin (+44 7747 113 930, jbenjamin@maitland.co.uk)

David Sturken (+44 7990 595 913, dsturken@maitland.co.uk)

Disclaimer

This press release does not contain or constitute an offer of securities for sale or an invitation or inducement to invest in securities in France, the United States or any other jurisdiction.

The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

The securities referred to herein may not be offered or sold in the United States of America absent registration or an applicable exemption from registration under the U.S. Securities Act of 1933, as amended. The Group does not intend to register all or any portion of the offering of the securities in the United States of America or to conduct a public offering of the securities in the United States of America.